Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Université de Montréal

$105,000.00

Pathophysiological role of kinin B1 receptor in type 2 diabetes and its interaction with TRPV1.

FY 2008-09

Summary
The growing proportion of aging population brings new challenge in medical care. Epidemiological studies reveal that the number of patients suffering of cardiovascular diseases and diabetes reaches epidemic level among industrial population. The World Health Organisation estimates that there will be 300 millions of clinically diagnosed type 2 diabetes worldwide by the year 2025. Furthermore, the complications of diabetes such as nephropathy, retinopathy and associated pain are still largely resistant to the current therapy. Peripheral diabetic neuropathies, among the most common complications of types 1 and 2 diabetes, affect about 50-60% of patients with diabetes mellitus and are recognised as the most difficult pain to treat. Ultimately, we have for objective to treat or relief the most common complications of diabetes such as hypertension and associated pain. Our research team has major interest on a small protein, named kinin B1 receptor (B1R). This protein, normally absent in our body, occurs in diseases and is believed to play a role in pain and inflammation. Our laboratory has shown that the inhibition of this protein could be beneficial in diabetes and its complications. A recent breakthrough discovery from our laboratory was the demonstration that the activation of the ionic channel (TRPV1) located at the membrane surface of neurons carrying pain sensation can induce the occurrence of this protein (B1R). Moreover, we demonstrated that the inhibition of TRPV1 with a specific drug prevents pain in an animal model of type 1 diabetes. This proposal aims to block TRPV1 with pharmacological drugs in type 2 diabetic mice to measure the impact on 1- the occurrence of B1R; 2- the symptoms and manifestations of diabetes such as hypertension, pain neuropathy, renal failure and retinopathy. Finally, we aim to determine how B1R can occur following TRPV1 stimulation. This work should permit to identity new medication in the treatment of diabetic complications.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
184662
Name
Talbot Sébastien
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Pathophysiological role of kinin B1 receptor in type 2 diabetes and its interaction with TRPV1.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Allodynia And Hyperalgesia; Autoradiography And Immunohistochemestry; Confocal Microscopy; Diabetes; Gene Expression Measurement By Qpcr; Insulino-Resistance; Kinin B1 Receptor; Neuropathic Pain; Peptide Pharmacology; Trpv1 Receptor
Abstract
The growing proportion of aging population brings new challenge in medical care. Epidemiological studies reveal that the number of patients suffering of cardiovascular diseases and diabetes reaches epidemic level among industrial population. The World Health Organisation estimates that there will be 300 millions of clinically diagnosed type 2 diabetes worldwide by the year 2025. Furthermore, the complications of diabetes such as nephropathy, retinopathy and associated pain are still largely resistant to the current therapy. Peripheral diabetic neuropathies, among the most common complications of types 1 and 2 diabetes, affect about 50-60% of patients with diabetes mellitus and are recognised as the most difficult pain to treat. Ultimately, we have for objective to treat or relief the most common complications of diabetes such as hypertension and associated pain. Our research team has major interest on a small protein, named kinin B1 receptor (B1R). This protein, normally absent in our body, occurs in diseases and is believed to play a role in pain and inflammation. Our laboratory has shown that the inhibition of this protein could be beneficial in diabetes and its complications. A recent breakthrough discovery from our laboratory was the demonstration that the activation of the ionic channel (TRPV1) located at the membrane surface of neurons carrying pain sensation can induce the occurrence of this protein (B1R). Moreover, we demonstrated that the inhibition of TRPV1 with a specific drug prevents pain in an animal model of type 1 diabetes. This proposal aims to block TRPV1 with pharmacological drugs in type 2 diabetic mice to measure the impact on 1- the occurrence of B1R; 2- the symptoms and manifestations of diabetes such as hypertension, pain neuropathy, renal failure and retinopathy. Finally, we aim to determine how B1R can occur following TRPV1 stimulation. This work should permit to identity new medication in the treatment of diabetic complications.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Talbot, Sébastien
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~